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Short-term survival after kidney transplantation is excellent, but long-term survival 
remains low and is equivalent to non-end stage renal disease patients with many 
invasive malignancies. The aim of the study was to explore vitamin D status in the 
early phase after transplantation as a prognostic marker for long-term graft- and 
patient survival. 
Methods 
All first-time kidney transplant recipients between October 2007 and October 2012 in 
Norway were included. Vitamin D was measured ten weeks post-transplant. 
Information on graft failure and death was obtained from the Norwegian Renal 
Registry.  
Results  
Seven hundred and sixty-two first-time kidney transplant recipients were included, 
median age 57 years, with a median follow-up of 82 months. In the follow-up period 
there were 172 graft failures (23%) and 118 deaths (15%). Eighty-six percent of the 
transplant recipients with sufficient vitamin D levels were alive with a well-functioning 
graft after five years using Kaplan-Meier survival estimates, compared with 79% and 
76% of the patients with vitamin D deficiency and insufficiency, respectively 
(p=0.006). 
Conclusion  
In a nation-wide cohort of 762 first-time kidney transplant recipients, long term graft- 
and patient survival were better in recipients with vitamin D sufficiency ten weeks 





Chronic Kidney Disease-Mineral and Bone Disorder is a term that encompasses a 
constellation of abnormalities in the calcium-phosphate homeostasis seen in most 
patients with chronic kidney disease (CKD). Disturbances in the mineral and bone 
metabolism develop early in the progression of the disease, leading to calcification of 
the vasculature and soft tissue, renal bone disease and increased cardiovascular 
morbidity and mortality1. Increased levels of fibroblast growth factor 23 (FGF23) and 
subsequent increased levels of parathyroid hormone (PTH) increase the urinary 
excretion of phosphate, reduce the production of active vitamin D, compensating and 
resulting in near-normal levels of serum phosphate and calcium. As the disease 
progresses towards end-stage renal disease (ESRD) the compensatory mechanisms 
are overwhelmed, resulting in hyperphosphatemia, hypocalcemia, abnormal bone 
turnover and extra-skeletal calcification2.  
Vitamin D3 (cholecalciferol) is important for calcium and bone homeostasis3. In 
humans, vitamin D3 is primarily produced from 7-dehydrocholesterol in the skin by 
exposure to sunlight, and only a small amount comes from dietary sources or 
supplements. Some supplements may contain the plant analog, vitamin D2 
(ergocalciferol). The formation of the fully active vitamin D metabolite, 1,25-
dihydroxyvitamin D (calcitriol), requires a two-step hydroxylation, the first step in the 
liver and the second step in the kidneys4. Vitamin D is essential for intestinal and 
renal handling of calcium and phosphate, as well as for bone turnover through 
interplay with PTH and FGF235,6. Serum levels of 25(OH)D reflect vitamin D body 
stores, and are used as a measure of vitamin D status7.  
A large number of observational studies indicate that vitamin D has a number of 
effects beyond the regulation of the mineral metabolism. The almost universal 
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presence of vitamin D receptors on different cell types may explain why 25(OH)D 
deficiency is associated with diseases such as cardiovascular disease8, cancer9, 
diabetes10, and overall mortality11.  
A kidney transplantation is the preferred renal replacement therapy for most patients 
with ESRD12, improving both quality of life, and long-term survival13. Short-term 
results after kidney transplantation are excellent. Long-term prognosis is better than 
in chronic dialysis, but annual rates of graft failure beyond the first year post-
transplant have remained largely unchanged since the 1990s14. Five year survival 
after transplantation is still comparable to the prognosis associated with many 
invasive malignancies15.  
The aim of the study was to explore the association between vitamin D status ten 
weeks post-transplant and long-term graft- and patient survival.  
 
Patients and methods 
The study is a prospective, observational cohort study, where all patients receiving a 
first-time kidney transplant between October 15th 2007 and October 18th 2012 in 
Norway were included. In Norway there is one solid organ transplantation center, 
Oslo University Hospital, Rikshospitalet (OUS-RH), serving the entire country, without 
selection bias. All 762 adult first-time single-kidney transplant recipients in the period 
were included in the study, Figure 1.  
The standard immunosuppressive regimen included the use of basiliximab and 
methylprednisolone induction. The maintenance immunosuppression consisted of a 
calcineurin inhibitor (CNI) in combination with mycophenolate (95%) and 
prednisolone (100%). From 2007 to 2011, tacrolimus (Tac) was the preferred CNI to 
patients younger than 50 years and ciclosporine A (CsA) to older patients, patients 
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with high BMI or impaired glucose tolerance. From 2012, tacrolimus was preferred 
CNI to all patients except those with impaired glucose tolerance. In the total cohort 
53% used Tac and 46% CsA. A mammalian target of rapamycin inhibitor (m-TOR) 
was substituted for a CNI in a small number of patients (n=10) due to side effects, 
and azathioprine was used in one patient in combination with CsA. National 
guidelines regulate choice of immunosuppressive regime, changes in regime and 
follow-up by local nephrologists. 
Approximately ten weeks post-transplant all patients were examined at the laboratory 
for Renal Physiology at OUS-RH. At this investigation, vital signs, blood pressure and 
clinical chemistry data were captured. In addition, patients were subjected to an 
aortic (carotid-femoral) pulse wave velocity (aPWV) investigation. Plasma and serum 
samples for analysis of 25(OH)D, neutrophil gelatinase-associated lipocalin (NGAL) 
and calcium propensity score (T50) were obtained and stored at -70º C in the 
Diagnostic and Treatment biobank “Nyrefysiologisk laboratorium” (Biobank nr. 266-
2005-142234). 25(OH)D was measured en bloc from the biobanked serum on the 
complete cohort in 2015, the results were not reported to the treating physicians.  
Patients with a functioning kidney-graft one-year post-transplant were invited to OUS-
RH for clinical examination and a laboratory follow-up. From 2009 a routine protocol 
kidney graft biopsy was included in the examination. Long-term outcomes were 
obtained from the Norwegian Renal Registry (NRR) where annual data is collected 
on the entire Norwegian transplant population. The reporting to NRR is closely 
monitored, and the reply-rate is close to 100%. The study was approved by the 
Regional Medical and Health Research Commities (REC) South-East Norway 
(2014/455). Written informed consent was obtained from all patients before any data 
and biological material was included in the NRR and the biobank at OUS-RH. 
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Patients were followed from time of transplantation until graft failure, death or end of 
study at October 18th 2017. 
Blood samples were collected from fasting patients, and routine lab samples were 
analyzed at the biochemical department at OUS-RH. 25(OH)D, T50 and NGAL were 
analyzed in biobanked serum at Stavanger University Hospital, Calciscon AG and 
OUS-RH, respectively.  
Serum creatinine values were calibrated to the isotope dilution mass spectrometry 
method (reference range: females 45-90 µmol/L; males 60-105 µmol/L), and eGFR 
was estimated using the CKD Epidemiology Collaboration equation16. Serum 
25(OH)D was quantified by liquid-liquid extraction, derivatization with 4-phenyl-1,2,4-
triazoline-3,5-dione reagent (PTAD, Sigma-Aldrich, St. Louis, MO, USA), and 
analyzed by liquid chromatography coupled with tandem mass spectrometry 
detection (LC-MS/MS) at the laboratory of medical biochemistry at Stavanger 
University Hospital. The previously reported method17 has been incorporated in the 
routine laboratory workflow with some modifications. Briefly, 50 µL serum is mixed 
with 350 µL of 0.2M magnesium sulfate in a 96-well deepwell plate followed by 900 
µL of acetone + heptane (1+1) containing 4 ng/mL of D6-labelled 25(OH)D3 and D3-
labelled 25(OH)D2. After one min shaking and centrifuging with 4000xG at 4°C for 11 
min, a 300 µL volume of the top heptane layer was transferred to a new 96-well 
microplate and evaporated to dryness in a vacuum centrifuge at 60°C for 30 min. 
Finally, 100 µL of 0.5 mg/mL PTAD in dry acetonitrile was added to the microplate, 
and 1 µL of sample volume was analyzed by an Acquity UPLC coupled to a Xevo 
TQ-S mass spectrometer (Waters, Milford, MA, USA). The analytes were separated 
on a 2.1 x 50 mm C18 BEH reversed phase column (Waters) and eluted in a mobile 
phase consisting of 61 % of acetonitrile mixed with 0.1 % ammonium hydroxide. 
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Measurement ranges were 1-350 nmol/L for 25(OH)D3 and 4-350 nmol/L for 
25(OH)D2. Method quality was monitored by four different quality control samples, 
resulting in a method CV of less than 6 %. The laboratory participates in the Vitamin 
D External Quality Assessment Scheme (DEQAS, London, UK) and has received the 
proficiency certificate for the analysis of 25(OH)D. We used the National Institute of 
Health definition for vitamin D levels, with vitamin D deficiency defined as serum 
25(OH)D concentrations <30 nmol/L (<12 ng/mL), insufficiency 30-50 nmol/L (12-20 
ng/mL), sufficiency >50 nmol/L (>20 ng/mL), and levels >125 nmol/L (>50 ng/mL) as 
potentially toxic levels18,19.  
NGAL is a small protein belonging to the lipocalin superfamily, which increases 
during cellular stress and in acute kidney injury20. NGAL was analyzed by enzyme 
immunoassay using antibodies from R&D systems (Stillwater, Minnesota, USA). 
Inter- and intraassay coefficients of variation of 4.8% and 2.3%, respectively.  
Calcification propensity score (T50) is a blood test evaluating the propensity of blood 
to resist calcification by measuring the calcification inhibitory forces present in 
individual blood samples. Short T50 is consistent with accelerated transformation and 
low calcification resistance, whereas delayed transformation reflects intact 
calcification resistance21. T50 was determined using a method that measures the time 
of in vitro transformation from primary to secondary calciprotein particles, and has 
been described previously21. 40µl serum was exposed to high and supersaturated 
concentrations of calcium (35µl) and phosphate (25µl) solutions in triplicate in 384-
well plates. The transformation step was monitored at 37°C using time-resolved 
nephelometry (bmg labtech, Ortenberg, Germany). Nonlinear regression curves were 
calculated to determine T50. The analytical coefficients of variation of standards 
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precipitating at 120, 260 and 390 minutes were 7.8%, 5.1% and 5.9% 
respectively21,22 .  
Aortic (carotid-femoral) pulse wave velocity (aPWV) is the gold standard for non-
invasive measurement of aortic stiffness23 and has previously been described in 
detail24. Shortly summarized, aPWV measurements were done in the morning with 
patients in a quiet room. aPWV was measured with the SphygmoCor apparatus 
version 8.0 (AtCor Medical, New South Wales, Australia), and a validated tonometer 
(SPT-304, Millar Instruments, Houston, Texas). Pulse waves in the carotid and 
contralateral femoral artery were measured sequentially, with femoral measurements 
done in the non-transplanted side. Integrated software was used to calculate carotid-
femoral pulse wave transit time with a simultaneously recorded electrocardiogram as 
reference. Pulse wave travel distance was measured as the distance from the 
suprasternal notch to the umbilicus plus ten cm based on recommendations by the 
manufacturer24.  
From 2009 a protocol graft biopsy was obtained 1 year±2 months post-transplant. 
Two cores were obtained with ultrasound guidance using an 18 gauge spring-loaded 
biopsy gun, one for histology (hematoxylin-eosin and saffron, periodic acid-Schiff and 
Masson trichrome) and one for C4d. Both biopsies contained at least one glomerular 
and one arterial profile and sufficient tubulointerstitial tissue to grade inflammation (i), 
tubulitis (t) interstitial fibrosis (ci), and tubular atrophy (ct). One year biopsy data was 
available in 510 of the 584 kidney transplantations done after 2009 included in this 
study. Some recipients did not have a functioning graft one year post-transplant, 
some refused the procedure, or were already biopsied on indication. Protocol 
biopsies were assessed by one of four dedicated renal pathologists and graded 
according to revisited Banff 2007 classification25. Interstitial fibrosis was scored from 
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Normally distributed data is presented as mean±SD, not normally distributed data as 
median and range. 
Survival analysis was performed using Kaplan Meier estimate and Cox proportional 
hazard analysis including 25(OH)D and other relevant parameters as explanatory 
variables. The selection of variables to be entered into the Cox regression model was 
based on clinical knowledge and previous publications. The proportionality 
assumption was checked using a log-minus-log plot. 
To compare the different variable-distribution between vitamin D groups, ANOVA was 
used in numeric variables, and chi-square in categorical variables. 
A linear regression model was performed with vitamin D as dependent variable and 
sex, age, BMI, ten-week eGFR, iPTH, calcium, phosphate, albumine, preTx diabetes, 
combined vascular morbidity (a history of coronary and/or cerebral and/or peripheral 
vascular disease), time on dialysis, rejection episodes and donor status (living vs 
deceased donor) as independent variables measured at ten weeks post-transplant. 
Three different Cox regression models were performed using death, graft failure and 
death-censored graft loss as dependent variables. Sex, age, BMI, ten-week eGFR, 
iPTH, calcium, vitamin D, phosphate, albumine, preTx diabetes, vascular 
comorbidity, time on dialysis, rejection episodes and donor status were used as 
independent variables in all models. All adjustment variables were set to their 
empirical means when computing the adjusted survival curves. Patients without 
events were censored at October 18th 2017. 
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ANOVA and paired samples t-tests were used to compare creatinine levels at ten 
weeks post-transplant and at one-year.  
Statistical analysis was performed using IBM SPSS Statistics 24. P-value ≤ 0.05 was 
considered statistically significant. 
 
Results 
Vitamin D status and renal diagnosis in first-time kidney transplant recipients  
From a total of 762 first-time transplant recipients, 148 (19%) had 25(OH)D levels 
<30 nmol/L (vitamin D deficiency), 351 (46%) had 25(OH)D levels from 30 to 50 
nmol/L (vitamin D insufficiency), and 263 (35%) had 25(OH)D levels >50nmol/L 
(vitamin D sufficiency) ten weeks post-transplant. None had 25(OH)D levels >125 
nmol/L. The baseline characteristics are given in Table 1. The most common causes 
for ESRD in this population are hypertensive nephropathy, glomerulonephritis, 
polycystic kidney disease, IgA nephropathy and diabetic nephropathy. The renal 
diagnoses for ESRD were not different between the groups of patients in the different 
vitamin D categories, Table 2. 
 
Predictors of vitamin D 
Patients with vitamin D sufficiency ten weeks post-transplant had significantly lower 
eGFR and higher cholesterol compared with patients with vitamin D deficiency and 
insufficiency, but a larger proportion had a pre-emptive transplant or a living donor 
graft. The prevalence of a history of cerebrovascular disease (transitory ischemic 
attack (TIA), cerebrovascular infarction or - bleeding) at time of transplantation was 
significantly higher in the group of patients with vitamin D insufficiency compared with 
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patients with vitamin D sufficiency, but creatinine levels were not different between 
the three groups. 
Seventy-one percent were treated with active vitamin D or vitamin D analogs prior to 
transplantation, and eight percent were treated with calcimimetics (six percent used a 
combination of the two), the distribution was equal in the three vitamin D groups, 
supplementary table 1. The use of vitamin D analogs and calcimimetics were stopped 
at the time of transplantation. Vitamin D measurement was not a part of standardized 
care between 2007 and 2012, anti PTH medication and active vitamin D was 
prescribed based on PTH and calcium levels post-transplant by the treating 
nephrologists. We have no data on native vitamin D treatment in the registry pre- or 
post-transplant. The vitamin D levels were not significantly different between patients 
transplanted in different seasons of the year. 
The linear regression model with vitamin D as dependent variable and eGFR, sex, 
age, BMI, iPTH, calcium, phosphate, albumine, diabetes, the combined vascular 
morbidity, time on dialysis, rejection and donor status (living vs deceased donor) as 
independent variables, left eGFR (p<0.001, β -0.132), iPTH (p<0.001, β -0.232) the 
combined vascular morbidity (p=0.003, β -4.669), albumine (p<0.001, β 0.870), donor 
status (p=0.011, β -3.655), months in dialysis (p=0.019, β -0.109) and age (p<0.001, 
β 0.203) as significant influencers on vitamin D, whereas sex (p=0.887, β -0.187), 
BMI (p=0.843, β -0.032), calcium (p=0.909, β -0.505), phosphate (p=0.538, β 0.979), 
rejection (p=0.648, β 1.664) and diabetes (p=0.058, β -3.312) did not significantly 
influence the model.   
 
Vitamin D status and long-term survival, univariate analysis 
14 
 
During a median (range) follow-up of 82 months (1-117) after the ten-week post-
transplant control, 118 (15%) recipients died, and 172 (23%) patients lost their grafts. 
The main causes of death were infection (n=37), malignancy (n=29) and cardiac 
arrest /myocardial infarction (n=27), table 3. 54 patients lost their grafts, of which 39 
were rejections, 5 recurrence of the primary kidney disease in the graft, 2 systemic 
infections and 8 “other”. The frequency of rejections was highest in the group with low 
vitamin D. 
Patient and graft survival were significantly better in patients with vitamin D 
sufficiency at ten weeks post-transplant compared with patients with vitamin D 
insufficiency or deficiency. Crude Kaplan-Meier estimated 5 year survival was 86±2% 
in recipients with vitamin D sufficiency, compared with 79±2% and 76±3% in 
recipients with vitamin D deficiency and insufficiency, respectively (p=0.006), Table 4. 
Using death as the main end-point, the risk of death was 2.3 (1.5-3.6) times higher in 
patients with vitamin D insufficiency and 1.8 (1.1-3.1) times higher in patients with 
vitamin D deficiency compared with patients with vitamin D sufficiency, Table 5, 
Figure 2.  
 
Vitamin D status and long-term survival, multivariable analysis 
In the adjusted model the patients with 25(OH)D levels <30 nmol/L, and patients with 
25(OH)D levels 30 - 50 nmol/L, had a risk of graft failure or death of 1.6 (1.1-2.4) and 
1.6 (1.0-2.7) times higher, respectively, as compared with patients with 25(OH)D 
levels >50 nmol/L, Table 5, Figure 3. Using graft failure as the main end-point, 
censoring for death with functioning graft, the results show the same tendency with 
1.5 (0.6-3.3) times increased risk of graft failure with vitamin D insufficiency and 1.3 
15 
 
(0.4-3.8) times increased risk of graft failure with vitamin D deficiency, Table 5, Figure 
4.  
In the Cox regression model with death as dependent variable, age, BMI, vitamin D 
level, iPTH, diabetes, donorstatus and months in dialysis were significantly 
associated with death, supporting that high age, low BMI, low vitamin D, long time in 
hemodialysis, deceased donor and the presence of diabetes are associated with 
death after kidney transplantation. Sex, eGFR at 10 weeks, calcium, phosphate, 
albumine, rejection episodes and vascular morbidity were not significantly associated 
with death, table 6. We found higher risk of death in the group with vitamin D 
insufficiency (p=0.04), than in the group with vitamin D deficiency (p=0.004) when 
comparing with vitamin D sufficiency, and overall vitamin D sufficiency shows 
superior survival (p=0.009) compared with the combination of the other two groups of 
patients, figure 2.  
When using graft failure as the dependent variable, 10 week eGFR and rejection 
episodes were significantly associated with graft loss, showing that low eGFR and 
acute rejections are all independent risk factors for graft loss. The vitamin D level 10 
weeks post-transplant trends towards a significant association with graft loss. Age, 
sex, BMI, iPTH, calcium, phosphate, albumine, diabetes, months in dialysis, donor 
status and vascular morbidity was not significantly associated with graft loss, table 6. 
Age, BMI, vitamin D level, donor status and time in dialysis were significantly 
associated with the combination of graft failure and death as the dependent variable. 
Sex, eGFR, calcium, phosphate, iPTH, diabetes, vascular morbidity and rejection 
episodes were not significantly associated with graft loss and death, table 6.  
The results in the Cox model remained unchanged whether vitamin D was treated as 
a continuous or a categorical variable.   
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Vitamin D level at ten weeks post-transplant was associated with graft failure and 
death in all three Cox models.  
 
Vitamin D status and vascular disease 
NGAL was not significantly different between the groups of patients with vitamin D 
insufficiency, deficiency and sufficiency, respectively (p=0.39). 
Mean T50 was 207 minutes (±74min), with significantly higher values in the vitamin D 
sufficient group of patients compared with the patients with vitamin D deficiency and 
insufficiency (p=0.037), the patients with vitamin D deficiency having lower values 
than the vitamin D insufficient patients.  
Median aPWV at ten weeks was 9.5 (4.1-24.9) m/s, with no significant difference 
between the vitamin D groups of patients (p=0.276). 
 
Vitamin D status and one-year follow-up 
One year post-transplant follow-up laboratory samples were analyzed in 710 (93%) of 
the 762 transplant recipients. Seventeen patients were dead or had lost their graft 
before one-year follow-up, and 35 declined to attend the one-year routine follow-up 
investigation. Mean serum creatinine levels in the 710 patients with vitamin D data at 
one-year was 121±40 µmol/L at ten weeks post-transplant, and 122±47µmol/L one-
year post-transplant, p=0.496. In the group of patients with vitamin D deficiency (137 
patients) creatinine increased non-significantly from 117±43µmol/L to 125±61 µmol/L, 
p=0.064, and in the group with vitamin D insufficiency (322 patients) the creatinine 
increased from 120±37 µmol/L to 122±43 µmol/L, p=0.201. In contrast, patients with 
vitamin D sufficiency (251 patients) had a significant decrease in creatinine, from 
124±36 µmol/L to 120±43 µmol/L, p=0.028. Creatinine increased ≥ 20% from week 
17 
 
10 to one-year post-transplant in 106 individuals (15%), 26 patients (20%) in the 
group with vitamin D deficiency, 55 patients (17%) with insufficiency and 23 patients 
(9%) with vitamin D sufficiency, p=0.004.  The levels of iPTH, phosphate, calcium 
and albumine were not significantly different ten weeks and one-year post-transplant 
in the different groups of patients (data not shown).  
In the one-year protocol biopsies, interstitial fibrosis was scored into four categories 
according to the Banff classification, score zero to three.  There was significantly 
more interstitial fibrosis, i.e. biopsies with fibrosis scores two and three compared 
with scores zero and one, in patients with vitamin D deficiency/insufficiency 
compared with the group of patients with vitamin D sufficiency (p=0.022). 
 
Discussion  
Vitamin D sufficiency (25(OH)D >50 nmol/L) ten weeks post-transplant was 
associated with better graft- and overall patient survival, better kidney graft function 
and significantly less interstitial fibrosis in the kidney grafts, compared with patients 
with vitamin D deficiency or insufficiency. Furthermore, the association between 
vitamin D levels and all outcomes persisted in adjusted analysis with predetermined 
conventional risk markers. 
25(OH)D deficiency is common in patients referred for kidney transplantation26. 
Prevalence varies across cohorts, reflecting different supplementation policies, 
sunshine exposure and co-morbidity. After a successful transplantation and restored 
kidney function, many transplant recipients remain 25(OH)D insufficient27.  
The prevalence of cerebrovascular disease before transplantation was slightly higher 
in the group of patients with vitamin D insufficiency. The prevalence of peripheral 
vascular- or coronary disease, aPWV or T50 as non-invasive measurements of aortic 
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stiffness and functional calcification resistance were not significantly different in the 
groups of patients. Higher aPWV and lower T50 at ten weeks post-transplant were 
however associated with death and graft failure supporting vascular disease as a risk 
factor. In general, the differences in baseline characteristics cannot explain the 
increased mortality and incidence of graft failure in patients with reduced vitamin D 
levels post-transplant. Unfortunately, delayed graft function is not registered in the 
NRR, thus we have not been able to include this possible confounder in the 
multivariate analyses. 
Serum creatinine decreased during the first year after transplantation and there were 
fewer patients with significant fibrosis in the one-year protocol biopsy in patients with 
vitamin D sufficiency compared with the other groups. Berchtold et al showed that 
high iPTH, low vitamin D and T50 were associated with interstitial fibrosis and 
vascular lesions in the kidney grafts, independently of eGFR28, supporting our 
findings. Others have found an association between low 25(OH)D levels three 
months post-transplant and a higher risk of rejection, increased interstitial fibrosis, 
lower eGFR and graft failure29-31. Low 25(OH)D levels measured on average six 
years post-transplant were in another study independently associated with increased 
mortality and a higher annual decline in eGFR32. It is a matter of debate if vitamin D 
is just a marker for increased mortality and graft failure in these patients, or if low 
vitamin D triggers a cascade of events leading to the actual findings. Due to the 
design of our study it is unfortunately not possible to investigate a cause-effect 
relationship. From prior studies it is however known that vitamin D deficiency 
increases the levels of FGF23 and decreases the levels of Klotho. High FGF23 levels 
are associated with increased mortality and cardiovascular death, and low Klotho 
with ageing and mortality33. Vitamin D is a pleiotropic hormone that affects most 
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tissues through the vitamin D receptors which are widely distributed throughout the 
body, interfering amongst other with the immune system34,35. The VITA-D study 
randomized adult kidney transplant recipients with vitamin D deficiency to treatment 
with oral vitamin D3 or placebo. With 1 year follow-up they did not find improved 
short-term outcome, possibly the opposite on the kidney grafts 36. To our knowledge, 
no other randomized study exploring the effect on these parameters and hard end-
points of vitamin D substitution in kidney transplant recipients have been performed, 
and follow-up time more than 1 year would be preferable. 
Studies on FGF23 and Klotho signaling pathways have revealed that high affinity 
binding of FGF23 to target cells depend on a receptor complex consisting of FGF 
receptors and Klotho37. A Klotho independent FGF23 signaling pathway, a 
calcineurin and nuclear factor of activated T-cells (NFAT) signaling, has recently 
been identified in the parathyroid glands as well as in the heart38-40. Calcitriol 
prevents cardiac hypertrophy by blocking the NFAT signaling in cardiac myocytes in 
uremic rats by selectively blocking FGF23 effects on the heart and thereby reducing 
hypertrophic growth of cardiac myocytes41. Low vitamin D levels are associated with 
disturbances in the FGF23/Klotho axis which may explain why low vitamin D levels 
are associated with reduced graft survival and increased morbidity and mortality. The 
associations between vitamin D and FGF23 and Klotho should be further explored in 
kidney transplant patients. 
A brief intervention study with paricalcitol two to four weeks prior to scheduled 
abdominal aneurysm repair resulted in a significant reduction in CD4+ T-helper cells, 
and reduction in CD3+T-cells, as well as reduction in IL-2, 4 and 10 in the aneurysm 
wall samples42. These findings support that paricalcitol as a vitamin D receptor 
agonist may have effects on local inflammation. Downregulation of the inflammatory 
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response may also explain the association between vitamin D levels in kidney 
transplant patients and the risk for interstitial fibrosis, graft failure and death. Another 
intervention study with paricalcitol post-transplant found a reduction in PTH but not in 
vascular health, or influence on allograft gene expression43. 
The potential effects of nutritional vitamin D supplementation represent an important 
question. In the general population and in patients with CKD, preliminary intervention 
studies suggest that restoring 25(OH)D levels with nutritional supplementation might 
reduce the risk of mortality44,45. Adequate powered randomized studies are needed to 
explore the effects of vitamin D supplementation in these patients.  
 
Strengths and limitations 
The investigated cohort of transplanted patients, represent the whole Norwegian 
cohort, without any selection bias with only one transplantation center. The NRR 
shows close to 100% national patient and data coverage. Routine laboratory samples 
were analyzed in the same laboratory both ten weeks and one-year post transplant 
(OUS-RH), and all the renal biopsies where performed and examined in the same 
department. The median follow-up period of 83 months is longer than in most other 
studies, and very few patients did not meet at the one-year investigation. We found a 
significant association between vitamin D levels 10 weeks post-transplant and death, 
vitamin D levels and graft loss showed a trend towards a significant association with 
a near-significant p-value. We believe that this may be due to a power problem, and 
that the association would be more significant with a higher number of included 
patients. Unfortunately, delayed graft function is not registered in the NRR, thus we 
have not been able to include this possible confounder in the multivariate analyses. 
The study is however, an observational study, and the conclusion is hypothesis 
21 
 
generating. Most patients were Caucasians, and the results cannot be extrapolated 
to transplanted patients with other ethnicities.  
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Males/ Females  515/ 247 95/ 53 242/ 119 178/ 85 0.62 
Age (years) 57 (16-82) 54 (17-80) 57 (19-82) 57 (16-77) 0.042 
BMI (kg/m²) 25.6±4.1 26.0±4.6 25.5±4.0 25.5±3.9 0.448 
Deceased donor, n, 
% 
495 (65%) 107 (72%) 239 (68%) 149 (57%) 0.001 
Preemptive Tx, n 
(%) 
224 (29%) 28(18%) 99 (28%) 97 (37%) 0.001 
Dialysis modality, 
HD/ PD 
386/ 152 88/ 32 173/ 79 125/ 41 0,306 
Months of dialysis 9 (0-90) 11 (0-64) 10 (0-85) 6 (0-90) 0.000 
eGFR 10 weeks 
(ml/min/1.73m²) 
59.3±20.1 63.9±23.5 59.3±20.2 56.6±17.4 0.002 
Creatinine (µmol/L) 121.1±38.7 117.3±43 121.2±38.6 123.5±35.8 0.306 
Calcium (mmol/L) 2.37±0.15 2.37±0.18 2.37±0.14 2.37±0.15 0.972 
Phosphate 
(mmol/L) 
0.89±0.39 0.89±0.23 0.89±0.52 0.90±0.20 0.805 
NGAL (ng/mL) 244.4±92.9 250.3±103.9 239.5±95.9 247.9±81.8 0.390 






9.8 (2.9-48) 0.000 
Albumine (g/L)  42.0±3.4 41.5±3.6 41.9±3.4 42.6±3.1 0.003 














85 (52-117) 84 (52-105) 85 (56-117) 85 (56-109) 0.297 




LDL (mmol/L) 3.9±1.2 3.7±1.3 3.9±1.2 4.1±1.2 0.003 
HDL (mmol/L) 1.5±0.5 1.3±0.5 1.5±0.5 1.5±0.4 0.000 
HbA1c (%) 5.9±0.94 5.9±1.05 5.9±0.95 5.8±0.86 0.229 
aPWV (m/s) 10.3±3.4  10.4±3.7 10.1±3.6 10.0±3.0 0.276 
T50 (min) 207±74 206±81 200±70 217±74 0.037 
Vascular morbidity, 
n (%) 
195 (26%) 45 (30%) 103 (29%) 47 (18%) 0.002 
          Cerebro 
vascular disease 
(incl TIA)              
54 (7%) 21 (14%) 24 (7%) 9 (3%) 0.001 
          Peripheral 
vascular disease 
88 (12%) 20 (14%) 42 (12%) 26 (10%) 0.571 
          Coronary 
disease 
126 (17%) 25 (17%) 69 (20%) 32 (12%) 0.047 




hypertrophy, n (%) 
108 (14%) 22 (15%) 51 (15%) 35 (13%) 0.880 
Diabetes, preTx, n 
(%) 
137 (18%) 37 (25%) 65 (19%) 35 (13%) 0.012 
Median and range for age, dialysis duration, iPTH and blood pressure, mean±SD for 
other normally distributed variables. ANOVA was used on numeric variables, chi 
square on categorical variables. 
 
BMI=body mass index, Tx=transplantation, HD= hemodialysis, PD=peritoneal 
dialysis, eGFR=estimated glomerular filtration rate, NGAL=neutrophil gelatinase-
associated lipocalin, iPTH=intact parathyroid hormone, LDL=low-density lipoprotein, 
HDL=high-density lipoprotein, BP=blood pressure, HbA1c=glycosylated hemoglobin, 
T50=calcification propensity score, aPWV= arterial pulse wave velocity, TIA= 




Table 2  
Renal diagnosis before transplantation 
















Hypertensive nephropathy 171 (22%) 34 (23%) 82 (23%) 51 (19%) 
Glomerulonephritis 137 (18%) 28 (19%) 68 (19%) 41 (16%) 
Polycystic kidney disease 134 (18%) 16 (11%) 63 (18%) 55 (21%) 
IgA nephropathy 86 (11%) 14 (10%) 32 (9%) 40 (15%) 
Diabetic nephropathy 83 (10%) 23 (16%) 43 (12%) 17 (6%) 
Pyelonephritis/interstitial 
nephritis 
38 (5%) 5 (3%) 15 (4%) 18 (7%) 
Tubulointerstitial nephritis 27 (3%) 5 (3%) 7 (2%) 15 (6%) 
Hereditary kidney disease 
(Alport, Cystinosis, Fabry etc) 
12 (2%) 
 
3 (2%) 7 (2%) 3 (1%) 
Renal malformations 7 (1%) 3 (2%) 3 (1%) 1 (0.5%) 
Wegeners granulomatosis 16 (2%) 2 (1%) 7 (2%) 7 (3%) 
Myelomatosis/Amyloidosis 9 (1%) 1 (1%) 5 (2%) 3 (1%) 
SLE 6 (1%) 2 (1%) 2 (1%) 2 (1%) 
Cortical or tubular necrosis 7 (1%) 2 (1%) 4 (1%) 1(0.5%) 
Uncertain etiology 12 (2%) 2 (1%) 6 (2%) 4 (1%) 






Causes of death 












Cardial events 27 6 19 2 
Infection 37 9 19 9 
Cerebrovascular 
events 
5 0 1 4 
Malignancy 29 4 18 7 













Kaplan-Meier estimates of survival with functioning graft 
 % alive with 
functioning graft 
after 1 year (±SE) 
% alive with 
functioning graft 
after 5 years (±SE) 
Estimated time 
to 75% survival 
All patients 
(n=762) 






















(graft failure and/ 
or death) 















Vit D >50 nmol/L Reference Reference Reference 
Vit D 30-50 
nmol/L 
1.7 1.2-2.5 1.1 0.6-2.1 1.8 1.1-3.1 















Vit D >50 nmol/L Reference Reference Reference 
Vit D 30-50 
nmol/L 
1.6 1.0-2.7 1.3 0.4-3.8 1.7 1.0-3.1 
Vit D <30 nmol/L 1.6 1.1-2.4 1.5 0.6-3.3 1.8 1.2-2.9 
 
 
*adjusted for the following variables: Sex, age, BMI,10 week eGFR, iPTH, calcium, 
phosphate, albumine, diabetes, vascular comorbidity, time on dialysis, rejection and 
donorstatus (living vs deceased donor). All adjustment variables were set to their 





P-values and hazard ratios with 95% confidence intervals in the Cox regression 
models 
 Combined end-point 
(graft failure and/ or 
death) 






































































































































































































































Donor- 0.049 0.62 0,386- 0.587 0.78 0.325- 0.026 0.53 0.302-
32 
 
status 0.997 1.889 0.928 
























Kaplan-Meier plot showing overall survival in patients with vitamin D insufficiency, 




Number at risk: 
 
VitD 0  20  40 60  80 100 End 
<30 148 143 133 123 91 32 0 
30-50  351 336 323 291 192 80 0 
>50 263 261 255 236 168 60 0 






Adjusted* cox survival curves showing graft survival in patients with vitamin D 
insufficiency, deficiency and sufficiency 
Number at risk 
VitD 0  20  40 60  80 100 End 
<30 148 141 126 113 81 26 0 
30-50  351 333 313 279 183 75 0 
>50 263 260 250 226 161 58 0 
Total 762 734 689 618 425 159 0 
 
 
*adjusted for the following variables: Sex, age, BMI,10 week eGFR, iPTH, calcium, 
phosphate, albumine, diabetes, vascular comorbidity, time on dialysis, rejection and 
donorstatus (living vs deceased donor). All adjustment variables were set to their 




Figure 4:  
Adjusted* cox survival curves showing death-censored graft survival in patients with 
vitamin D insufficiency, deficiency and sufficiency 
 
Number at risk 
 
VitD 0  20  40 60  80 100 End 
<30 148 141 126 113 81 26 0 
30-50  351 333 313 279 183 75 0 
>50 263 260 250 226 161 58 0 
Total 762 734 689 618 425 159 0 
 
 
*adjusted for the following variables: Sex, age, BMI,10 week eGFR, iPTH, calcium, 
phosphate, albumine, diabetes, vascular comorbidity, time on dialysis, rejection and 
donorstatus (living vs deceased donor). All adjustment variables were set to their 
empirical means when computing the adjusted survival curves. 
 
 
